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Annexin-VHere we investigated alterations in the protein proﬁle of Hep-2 treated with red propolis using
two-dimensional electrophoresis associated to mass spectrometry and apoptotic rates of cells treated
with and without red propolis extracts through TUNEL and Annexin-V assays. A total of 325 spots were
manually excised from the two-dimensional gel electrophoresis and 177 proteins were identiﬁed using
LC–MS–MS. Among all proteins identiﬁed that presented differential expression, most were down-
regulated in presence of red propolis extract at a concentration of 120 lg/mL (IC50): GRP78, PRDX2,
LDHB, VIM and TUBA1A. Only two up-regulated proteins were identiﬁed in this study in the non-
cytotoxic (6 lg/mL) red propolis treated group: RPLP0 and RAD23B. TUNEL staining assay showed a
markedly increase in the mid- to late-stage apoptosis of Hep-2 cells induced by red propolis at concen-
trations of 60 and 120 lg/mL when compared with non-treated cells. The increase of late apoptosis was
conﬁrmed by in situ Annexin-V analysis in which red propolis extract induced late apoptosis in a dose-
dependent manner. The differences in tumor cell protein proﬁles warrant further investigations including
isolation of major bioactive compounds of red propolis in different cell lines using proteomics and molec-
ular tests to validate the protein expression here observed.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Propolis is a natural resinous product of honeybees that has
been used for centuries in traditional medicine all over the world
(Burdock, 1998; Castaldo and Capasso, 2002; Daugsch et al.,
2008). The propolis’ composition varies according to its botanical
origin; generally contains resin, wax, pollen, essential and aromatic
oils (Lustosa et al., 2008; Sforcin, 2007). Since 2007, the red prop-
olis type from the northeast of Brazil has been an important source
of investigation by local and international research groups. Its
botanical origin is from Dalbergia ecastophyllum (L) Taud.
(Leguminosae), a plant that characterizes the red color found inthe propolis (Daugsch et al., 2008; Franchi et al., 2012; Piccinelli
et al., 2011; Silva, 2007). Red propolis has shown several important
biological activities such as: antibacterial (Cabral et al., 2009; Righi
et al., 2011), antifungal (Siqueira et al., 2009), anti-inﬂammatory
(Barreto, 2008; de Almeida et al., 2013), antiulcerative (Pinheiro,
2009), antioxidant (Cabral et al., 2009; Righi et al., 2011), and
antitumor (Alencar et al., 2007; Li et al., 2008). The propolis antitu-
mor activity has been widely studied (Valente et al., 2011) because
of growing interest on strategies for prevention and treatment of
cancer (Akyol et al., 2013). The resistance mechanisms to cancer
drugs promote the development of new medicines with potential
source of novel bioactive molecules (Umthong et al., 2011).
We have recently reported that red propolis extracts are com-
posed of complex molecules and exhibits important biological
properties with capacity to scavenge free radicals and to inhibit
tumor cell growth in a selective manner when compared to
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used 2-DE associated to mass spectrometry to reveal the protein
proﬁles of Hep-2 cells and apoptotic rates of cells treated with
and without red propolis extracts through TUNEL and Annexin-V
assays.2. Materials and methods
2.1. Red propolis sample and preparation of red propolis extract
Red propolis was collected in the year 2010, one sample per month, in the Cap-
ivara Apiary in Brejo Grande, state of Sergipe in the northeast of Brazil (102802500S
and 362601200W). The propolis was protected from light and frozen at 20 C until
extract preparation was proceeded. The twelve samples of red propolis was ground
to a ﬁne powder forming a pool and 1 g (dry weight) was mixed with 10 mL of
EtOH–H2O 70–30% (v/v) and shaken at room temperature for 24 h. After extraction,
the mixture was ﬁltered and the solvent was evaporated and produced a red ﬁne
powder. The dry extract was kept frozen at 20 C and prepared at different con-
centrations with EtOH–H2O 50% (v/v), and ﬁnally ﬁltered through a 0.22 lm polye-
thersulfone membrane (TPP, Techno Plastic Products, Switzerland). This sample
was chemically analyzed as well its antioxidant and antitumor activities, with re-
sults cited by Frozza et al. (2013).
2.2. Cell culture and red propolis treatment
Hep-2 (human laryngeal epidermoid carcinoma cells) was obtained by the
American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were grown
in Dulbecco’s modiﬁed eagle’s medium–high glucose (DMEM) supplemented with
10% (w/v) heat-inactivated fetal bovine serum (FBS) and 1% (w/v) penicillin–strep-
tomycin. The culture was maintained in a humidiﬁed atmosphere at 37 C, 5% CO2
and 95% air. The study was performed when cells reached 70–80% conﬂuence.
Cells (2.6  106) were seeded into 75 cm2 culture ﬂasks with supplemented cul-
ture medium. After 24 h, cells were treated and exposed for 1 h at different propolis
concentrations. The negative control group (Group A) was treated with the same
amount of hydroalcoholic solution used in the group with propolis extract. The
other two groups received red propolis extract at two different concentrations,
6 lg/mL (Group B) and 120 lg/mL (Group C) in free FBS medium and incubated
at 37 C in 5% CO2.
Extract concentrations were determinated according to previous 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-dipheyl-tetrazolium bromide (MTT) survival experiments re-
ported by our group (Frozza et al., 2013), showing non-cytotoxic dose (6 lg/mL)
and dose that inhibits cell growth by 50% – IC50 (120 lg/mL). Experimental proce-
dures were performed at least in triplicate.
2.3. Protein extraction
Cells were harvested and lysed in 0.5 mL of lysis buffer (7 M ureia, 2 M thiourea,
40 mM Tris base pH 8.5, 20 mM DTT, 4% (w/v) CHAPS and 1% (w/v) protease inhib-
itor). After 30 min at room temperature, shaking at 90 rpm, the lysate was scraped,
transferred into microtubes and centrifuged at 14,000 rpm for 30 min at 4 C. The
supernatant was collected and frozen at 20 C. The procedure was repeated twice
and a pool of extract was analyzed.
The samples were dialyzed for 24 h, at 4 C, with gentle agitation on a magnetic
stirrer, changing four times Milli-Q water every 6 h. Bradford assay (BioRad Labora-
tories, Hercules, CA) was used to determine protein quantiﬁcation according to
manufacturer’s instructions. The samples were frozen at 80 C, lyophilized (Lab-
conco FreeZone, Labconco Corporation, USA) and the pellets were suspended in
25 mM (w/v) Tris HCl pH 7.4 and processed with the Clean Up Kit (GE Healthcare,
USA).
2.4. 2-D gel electrophoresis
Protein extracts containing 900 lg of total protein were diluted in IPG rehydra-
tion buffer (7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 1% (w/v) DTT, 0.01% (w/v) bro-
mophenol blue, 0.2% (v/v) ampholytes). The protein samples were refrigerated at
4 C for 40 min and centrifuged at 20,800g for 40 min at 20 C. The supernatants
were loaded onto 17 cm IPG strips with pH 4–7 gradient. Proteins were focused
at 20 C according to the following program: 15 min, 250 V; 3 h, gradient to
10,000 V; 6 h, 10,000 V until 60 kVh in a Protean IEF cell system (BioRad Laborato-
ries, Hercules, CA). Samples were equilibrated for 15 min in a buffer containing 6 M
urea, 30% (v/v) glycerol, and 1% (w/v) DTT and for 15 min in the same buffer but
with DTT replaced by 4% (w/v) iodoacetamide. The second dimension was SDS-
PAGE in 12% polyacrylamide in a PROTEAN II xi 2D Cell apparatus (BioRad Labora-
tories, Hercules, CA). Electrophoresis was performed at 40 mA/gel for 30 min and at
50 mA/gel. The spots were stained with Colloidal Coomassie (2% (v/v) phosphoric
acid, 20% (v/v) methanol, 10% (w/v) ammonium sulfate, 0,05% (w/v) Coomassie Bril-
liant Blue G-250.2.5. Image analysis of differential protein expression
Two-dimensional images were captured by scanning the stained gels with Im-
age Scanner III (GE Healthcare, USA), digitalized with LabScan™ v. 6.0 software and
analyzed with the ImageMaster™2D Platinum 7.0 software (GE Healthcare, USA).
Three gels of each treatment obtained from a pool of three independent cultures
were analyzed to guarantee representative results. Each treatment showed less
than 10% variability in the number of protein spots detected among replicates. Spot
normalization, as an internal calibration to make the data independent from exper-
imental variations among gels, was made using relative volumes to quantify and
compare the gel spots.
2.6. In-gel digestion and protein identiﬁcation by mass spectrometry
The protein spots of interest were manually excised from Colloidal Commassie
stained gels by biopsy punches, placed in a microtube, and washed twice with 50%
(v/v) acetonitrile and 25 mM ammonium bicarbonate for 15 min each. Subsequent
washing with acetonitrile was performed before the samples dried at room temper-
ature and digested overnight using modiﬁed trypsin (Sigma) diluted in 25 mM
ammonium bicarbonate at 37 C. Next, peptides were extracted in two washing
steps with 50% (v/v) acetonitrile and 5% (v/v) triﬂuoroacetic acid for 1 h and dried
in a vacuum centrifuge. To identify proteins, we used a liquid chromatography
(LC) separation (reversed-phase HPLC) (nanoACQUITY, Waters, Milford, USA) cou-
pled with tandem mass spectrometry (MS) as detector with an electrospray ioniza-
tion (ESI) quadrupole and time-of-ﬂight (Q-ToF) (Q-ToF Micro, Waters Micromass,
Milford, USA) coupled to a capillary liquid chromatography system (nanoAcquity
UPLC, Waters, Milford, USA). A nanoﬂow ESI source was used with a lockspray
source for lockmass measurement during all the chromatographic runs.
Peptides were identiﬁed by matching the measured monoisotopic masses to
theoretical monoisotopic masses generated using the MASCOT search via in silico
digest through the NCBI-NR (Non-Redundant Protein Sequences database). For pro-
tein identiﬁcation, the resulting MS data was interpreted by MASCOT software (Ma-
trix Science, London, UK) against NCBInr database. During the database searching,
one missed cleavage per peptide was set as the maximum allowance, a mass toler-
ance of 0.2 Da, and MS/MS tolerance of 0.2 Da was also used according to prede-
ﬁned protocol. Other possible variations, such as carbamidomethylation for
cysteine and oxidation for methionine, were also taken into account.
2.7. Flow cytometry TUNEL apoptosis assay
Hep-2 cells were treated with 6, 60 and 120 lg/mL of red propolis for 1 h, fol-
lowed by cultivation in extract-free medium for 24 h and the Guava TUNEL assay
(Guava Technologies) was conducted following the manufacturer’s instructions.
Brieﬂy, Hep-2 treated cells were subjected to cells ﬁxation procedure with 50 lL
of 4% (w/v) paraformaldehyde in PBS for 60 min at 4 C and then with 200 lL of
ice-cold 70% (v/v) ethanol at 20 C for at least 18 h. For staining procedure,
1.5  104 to 1.0  105 of ﬁxed cells was washed twice and was added to 25 lL of
DNA Labeling Mix for 60 min at 37 C. At the end of the incubation time, cells were
centrifuged and resuspended in 50 lL of the Anti-BrdU Staining Mix. Cells were
incubated in the dark at room temperature for 30 min and samples were acquired
on the ﬂow cytometry (Guava Flow Cytometry easyCyte™ System; Millipore Cor-
poration™). In this assay, terminal deoxynucleotidyl transferase (TdT) catalyzes the
incorporation of BrdU residues into the fragmenting nuclear DNA of apoptotic cells
at the 30-hydroxyl ends by nicked-end labeling. TRITC-conjugated anti-BrdU anti-
body binds to the incorporated BrdU residues, labeling the mid- to late-stage apop-
totic cells.
2.8. Morphological examination of cancer cells
Cells were seeded into 24-well plates containing coverslips. After 24 h incuba-
tion, the cells were treated with red propolis hydroalcoholic extract at 6, 60 and
120 lg/mL for 1 h, followed by cultivation in extract-free medium for 24 h. The neg-
ative control group was treated with EtOH–H2O 50% (v/v) instead of extract for the
same period. Then they were stained with Giemsa Stain (Accustain – Sigma–Al-
drich) according standard giemsa procedure established by the supplier. Morpho-
logical changes of the cells were observed and photographed under a light
microscope at 200 (Olympus).
2.9. Detection of late apoptosis by in situ analysis
Apoptotic cell death was detected and visualized by ﬂuorescence microscopy
using Annexin-V staining. Apoptosis is associated with characteristic morphological
and biochemical changes, including cell shrinkage, membrane blebbing, chromatin
condensation, DNA fragmentation, and cell surface changes (Reed, 2000). Annexin is
presented in several cellular functions and mainly characterized by their ability to
reversibly interact with membranes in a calcium-dependent manner (Lizarbe et al.,
2013). Annexin-V is used for apoptosis detection in cell cultures, and also for in vivo
molecular imaging (Lizarbe et al., 2013). The assay is based on the observation of
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types and by many apoptotic stimuli. On the cell surface it can be detected by bind-
ing ﬂuorochrome-tagged Annexin-V (Reed, 2000).
The Hep-2 cells were seeded into the coverslips into 24-well plates at 1.0  105
cells/mL in 500 lL of supplemented culture media. After 24 h, cells were treated
with 60 and 120 lg/mL of red propolis extract and negative controls were treated
with the same amounts of hydroalcoholic solution, incubated at 37 C in 5% CO2
for 1 h, followed by cultivation in extract-free medium for 24 h. Next, the medium
was removed and the cells were incubated with 2.5 lg/mL of Annexin V (abcam –
ab14196) primary antibody diluted in biding buffer (Hepes 10 mM, NaCl 150 mM,
KCl 5 mM, MgCl2 1 mM, CaCl2 1.8 mM pH 7.4) for 30 min. They were washed once
with binding buffer, then incubate with 2.5 lg/mL Dylight 488 (abcam –
ab115637) secondary antibody. The cells in the late apoptosis or necrosis were
staining either with propidium iodate (Sigma–Aldrich – P4170). Brieﬂy, they were
ﬁxed with formalin 4% for 15 min. The apoptosis was analyzed by ﬂuorescent
microscope (Olympus). The percentage of cells undergoing early (Annexin-V posi-
tive) or late (Annexin-V positive/PI positive) apoptosis was estimated by counting
at least 500 cells in a total of three test and expressed as a percentage of the total
number of cells.2.10. Statistical analysis
The results are expressed as the means ± SD obtained from three independent
experiments. Statistical signiﬁcance was evaluated using the Levene test followed
by analysis of variance (ANOVA) and Tukey’s post-hoc test for Annexin-V assay,
for TUNEL was used Chi-Square test and for proteomic data, statistical analysis
was performed using t tests. A p-value <0.05 was considered signiﬁcant using the
Statistical Package for Social Sciences (SPSS, version 19.0) for Windows.3. Results
Protein spots were manually excised from 3 groups of pH 4–7
and 2-DE map gels that received different concentration of red
propolis extract compared to an untreated control group. Alto-
gether, 325 spots were excised and submitted to identiﬁcation.
All spots from group A (control) were excised (n = 251) and only
differentially expressed spots from the treated groups (B and C)
were submitted to identiﬁcation according to differences in protein
proﬁles observed in the ImageMaster™ 2D Platinum software
(Fig. 1). Therefore, 65 spots were excised from group B and only
9 spots from group C. The identiﬁed proteins are listed in
Supplementary Table S1 and Table 1.
Altogether, MS allowed the identiﬁcation of 177 proteins out of
325 spots analyzed. The molecular mass (MW) and the isoelectric
point (pI) of each protein spot were experimentally determined
and compared with theoretical molecular mass and pI taken from
Mascot database and are listed in Supplementary Table S1. Many of
the gel-estimated MW/pI corresponded well to the theoretical val-
ues. Different levels of post-translational modiﬁcation, however,
could reveal distinct values from experimentally determined MW
and/or pI from the predicted ones. In addition, in most cases,
different isoforms were identiﬁed for a given protein.
All proteins identiﬁed were distributed according to the
Eukaryotic Orthologous Groups (KOG-NCBI) functional classiﬁca-
tion (Supplementary Table S1). The proteins from control are pre-
sented in Supplementary Fig. S1 by percentage of their KOG
classiﬁcation. Most of the proteins are related to posttranslational
modiﬁcation, protein turnover and chaperones (O), cytoskeleton
(Z), translation, ribosomal structure and biogenesis (J), transcrip-
tion (K), RNA processing and modiﬁcation (A) and intracellular
trafﬁcking, secretion and vesicular transport (U). Only 8% of the
identiﬁed proteins could not be classiﬁed (X). Selections of identi-
ﬁed proteins that presented expression in the control group and
were down- and up-regulated in the red propolis treated group
are represented with fold changes in Table 1.
Five proteins were identiﬁed as down-regulated in the group
treated with 120 lg/mL of hydroalcoholic extract of red propolis
(Fig. 1C) compared to the control group (Fig. 1A): 78 kDa glu-
cose-regulated protein (GRP78 – control spot 54/propolis IC50 spot
268), thiol-speciﬁc antioxidant protein (PRDX2 – control spot 122/propolis IC50 spot 314), L-lactate dehydrogenase B chain (LDHB –
control spot 138/propolis IC50 spot 293), vimentin (VIM-control
spot 79/propolis IC50 spot 307) and alfa-tubulin (TUBA1A – control
spot 74/propolis IC50 spot 298). Two proteins were up-regulated in
the red-propolis treated group (Fig. 1B) using non-cytotoxic con-
centrations of extract (6 lg/mL) compared to the control group
(Fig. 1A): UV excision repair protein RAD23 homolog B isoforms
1 (RAD23B – control spot 67/propolis non-cytotoxic spot 321)
and 60 acidic ribosomal protein P0 (RPLP0 – control spot 143/prop-
olis non-cytotoxic spot 323). All spot numbers are presented in
Supplementary Table S1 and differential expressed proteins are
seen in Figs. 1 and 2, at a maximized perspective.
Some of the proteins identiﬁed above are related to induction or
suppression of apoptosis. Thus, tests were carried out to verify the
relationship between the extract of red propolis and apoptosis
induction. Red propolis activity has shown to promote apoptosis
in other cancer cells models like MCF-7 (Kamiya et al., 2012) and
Nalm16 (Franchi et al., 2012).
TUNEL staining assay was performed to further elucidate the
mid- to late-stage apoptosis of Hep-2 cells induced by red propolis.
TRITC-conjugated anti-BrdU antibody binds to the incorporated
BrdU residues in those cells that exposed 30-hydroxyl ends in the
nuclear DNA, a characteristic feature of apoptotic cells. Fig. 3 dem-
onstrates that red propolis at concentrations of 60 and 120 lg/mL
presented a higher percentage (P < 0.05) of TUNEL–staining cells
when compared with the control group, with mean values of
33.5%, 63.5% and 4.5%, respectively. Moreover, red propolis at
6 lg/mL presented a similar percentage of apoptosis compared
with the control group (4.7%) and no difference between these
two groups were observed (P < 0.05).
The examination of cancer cells through Giemsa staining re-
vealed altered morphological structure according to the concentra-
tion of red propolis extract used. The cells in the negative control
group that received hydroalcoholic solution of 50% (v/v) presented
a rounded-like morphology (Fig. 4A), surrounded by abundant
cytoplasm, well deﬁned and intact, represented as healthy cells.
Similar morphological patterns were observed in the cell culture
that received 6 lg/mL red propolis extract treatment (Fig. 4B).
However, the cells that received treatment higher concentrations
of red propolis like 60 lg/mL (Fig. 4C) and 120 lg/mL (Fig. 4D) pre-
sented detachment and shrinkage, indicating several biological
changes upon extract activity that suggests cytotoxic activity
against the tumor cell lineHep-2.
Red propolis extract induced apoptosis in Hep-2 cancer cells in
a dose-dependent manner. According to Fig. 5, Annexin-V labeling
without PI uptake (green ﬂuorescence) indicates phosphatidylser-
ine detection on the external surface of an intact plasma mem-
brane. PI staining (red ﬂuorescence) in conjunction with
Annexin-V labeling (Merge – yellow ﬂuorescence) indicates a com-
promised membrane that may result from either late apoptosis or
necrosis. According to Fig. 6 the signaling to late apoptosis/necrosis
increased in a signiﬁcant way in the cells treated with 120 lg/mL
(98.46 ± 0.77%) comparing with that ones that received 60 lg/mL
(8.68 ± 2.84%) of red propolis extract and control group
(1.26 ± 0.41%).4. Discussion
We have recently shown that red propolis is composed of com-
plex molecules and exhibits important biological properties with
capacity to scavenge free radicals and to inhibit tumor cell growth
in a selective manner (Frozza et al., 2013). It is expected that prop-
olis affects the metabolism pathways and cellular activity after
treatment and cells may switch towards several different functions
before being rescued and programmed to die. To investigate how
Fig. 1. 2-DE proﬁles of the control (A) and red propolis treated group (B, 6 lg/mL; C, 120 lg/mL). Total protein extracts were separated on pH 4–7, 17 cm IPG strips, following
by 12% SDS-PAGE and staining with CBB R-250. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 1
Identiﬁcation of differentially expressed proteins in Hep-2 cells from control and treated groups.
Gene name Expression (%Vol)a Fold changeb KOGc Protein description
Controld Treatmente Control/treatment
120 lg/mL 6 lg/mL
DOWN-REGULATED
GRP78 0.416 ± 0.022 0.208 ± 0.028 2.00 O 78 kDa Glucose-regulated protein precursor
PRDX2 0.272 ± 0.011 0.200 ± 0.010 1.36 O Thiol-speciﬁc antioxidant protein
LDHB 0.548 ± 0.022 0.080 ± 0.006 6.85 C L-Lactate dehydrogenase B chain
VIM 0.167 ± 0.007 0.119 ± 0.010 1.40 Z Vimentin
TUBA1A 0.193 ± 0.007 0.030 ± 0.001 6.43 Z Alfa-tubulin
UP-REGULATED
RAD23B 0.069 ± 0.001 0.087 ± 0.001 0.79 L UV excision repair protein RAD23 homolog B isoforms 1
RPLP0 0.240 ± 0.010 0.319 ± 0.002 0.75 J 60 Acidic ribosomal protein P0
In t-test, all changes in%Vol between control and treated groups were signiﬁcant (P < 0.05).
a %Vol represents a normalized value of a relative volume of a spot taken from ImageMaster™ 2D Platinum 7.0.
b Fold change (control vs. treatment) calculated dividing the% (vol) from control gels by the% (vol) from propolis treated gels.
c KOG database functional classes: C – energy production and conversion; J – translation, ribosomal structure and biogenesis; L – replication, recombination and repair; O –
post-translational modiﬁcation, protein turnover, chaperons; Z – cytoskeleton.
d Control group, treatment with hydroalcoholic solution instead of propolis.
e Propolis treated groups: 120 lg/mL (IC50) and 6 lg/mL (not cytotoxic).
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sponses in Hep-2, this study generated protein proﬁles from cells
treated with or without red propolis extracts.
This is the ﬁrst study using red propolis from northeast of Brazil
associated to 2-DE SDS-PAGE and mass spectrometry that reports
alterations in the protein proﬁle using Hep-2 cells as experimental
model. The results showed differences in protein patterns between
the analyzed treated and untreated groups. There are several pro-
teomic studies on Hep-2 models submitted to a variety of extractsand culture conditions, which allow the identiﬁcation of differen-
tially expressed proteins (Bianchi et al., 2011; Mukhopadhyay
et al., 2006; Okoli et al., 2007; Rodrigues-Lisoni et al., 2010). So
far, however, there are no reports using proteomics with Brazilian
red propolis in any kind of tumor cell line.
Altogether, a total of 325 spots from both control and treated
groups were excised, in-gel digested with trypsin, and 177 proteins
were identiﬁed. Different isoforms were identiﬁed for a given pro-
tein, considering this, 113 different proteins were found. All spots
Fig. 2. Magniﬁed view expression proﬁle of the 7 signiﬁcant altered proteins: 5 down-regulated in the C panel from Figs. 1 and 2 up-regulated in the B panel form Fig. 1.
Fig. 3. TUNEL assay analysis of Hep-2 cells treated with 6, 60 and 120 lg/mL of red propolis and control group, after 1 h of exposure, followed by cultivation in extract-free
medium for 24 h. (A) Flow cytometry graphs and (B) percentage of mid- to late-apoptotic cells. Different letters (a and b) indicate signiﬁcant differences between the means
and differences were considered signiﬁcant at P < 0.05 (Chi-Square test).
Fig. 4. Morphological structure of cancer cells Hep-2 through Giemsa Stain. (A) Control, (B) treatment with 6 lg/mL red propolis extract, (C) Treatment with 60 lg/mL red
propolis extract and (D) treatment with 120 lg/mL red propolis extract. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
Fig. 5. Detection of cell apoptosis by in situ Annexin-V immunostain. Tumor cells were grown on glass slides and treated for 1 h (control, 60 lg/mL, 120 lg/mL) and then were
submitted to indirect immunoﬂuorescence. Representative photographs of the triplicate were taking under ﬂuorescent microscopy at 200. Healthy cells presented no
staining, early apoptotic cells (stained with Annexin-V) emitted green ﬂuorescence and late apoptotic cells (stained with Annexin-V and PI) are shown in yellow (Merge). The
cells stained only with PI emitted red ﬂuorescence. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
C.O. da Silva Frozza et al. / Food and Chemical Toxicology 63 (2014) 195–204 199from the control group were digested and only a few selections
of spots from the red propolis extract treated groups were
removed according to differential protein maps generated fromImageMaster™ 2D Platinum software. We have found several cases
in which more than one spot was assigned to the same protein.























Fig. 6. Percentage of cells immunostained in late apoptosis (Annexin V positive + PI
positive) by in situ analysis. Results were obtained from three independent
experiments expressed in median ± SD. ⁄represent statistical signiﬁcance according
Levene test followed by analysis of variance and Tukey’s post hoc test (p 6 0.05).
200 C.O. da Silva Frozza et al. / Food and Chemical Toxicology 63 (2014) 195–204important post-translational modiﬁcations, ranging from chemical
modiﬁcations to proteolytic cleavage. Among all proteins identiﬁed
that presented differential expression, the majority were down-
regulation in presence of red propolis extract at a concentration
of 120 lg/mL (IC50): GRP78, PRDX2, LDHB, VIM, TUBA1A (Table 1).
Cell rescue proteins like heat-shock (Hsps) or Hsp-related are a
family of proteins and examples of molecules involved in the deg-
radation or reactivation of damaged molecules and expected to be
up-regulated under stress conditions. Hsps are normally found in
response to stressful stimuli, including chemotherapeutic agents,
and response in carcinogenesis may be related to their activities
as chaperones, altering protein expression on tumor cells, espe-
cially proteins related to tumor progression and components of
the cell cycle (Myung et al., 2004). There are reports, however, indi-
cating down-regulation of some of the members of the heat-shock
protein family under stress conditions. HSp27 expression was re-
duced in human breast adenocarcinoma adriamycin-resistant and
paclitaxel-resistant cell lines in comparison to the parental cell
ones (Chuthapisith et al., 2007) and in human cells of hepatocarci-
noma in response to capsaicin treatment (Baek et al., 2008). We ob-
served that a member of the HSP70 family, the GRP78 protein, was
down-regulated in the propolis treated group. It has been previ-
ously reported that HSP27 and HSP70 function as antiapoptotic
proteins, while HSP60 and HSP10 as proapoptotic (Garrido et al.,
2001), which could explain the down-regulation of a member of
the HSP70 (GRP78) associated to cytotoxic response of propolis
in Hep-2 cells at IC50 levels.
GRP78 is a protein that modulates endoplasmatic reticulum
function showing prosurvival and anti-apoptotic properties in can-
cer metabolism (Chiu et al., 2008; Wang et al., 2009). It is believed
that GRP78 can interact and inhibit the activation of apoptosis
pathway components related to a series of molecules. It is reported
to be induced in a variety of cancer cells and drug-resistance lines
(Li and Lee, 2006). Chiu et al. (2008) demonstrated that knockdown
by siRNA of GRP78 reduced the malignant phenotype, inhibiting
cell growth and preventing cell migration and colony formation
on several types of head and neck cancers. Knockout of GRP78 also
seems to enhance apoptosis in colon cancer cells, generate resis-
tance to epirubicin (Chang et al., 2012) and paclitaxel (Mhaidat
et al., 2011). Chemoresistance of various cells correlates with
GRP78 expression and apoptosis inhibition (Jiang et al., 2009;
Wang et al., 2009; Zhang et al., 2006; Zhou et al., 2011). Despite
most studies indicate prosurvival and anti-apoptotic properties of
GRP78, some reports reveal the increase expression of this proteinupon treatment with drugs as vorinostat (Bianchi et al., 2011;
Kahali et al., 2010).
Tumors present a metabolic environment normally acidic, hyp-
oxic, and deprived from nutrients like glucose and amino acids, due
to rapid proliferation, elevated glucose intake, and sometimes poor
vascularization (Wang et al., 2009). Microenvironment of tumor
cells may be similar to a physiological stress condition and cells
manage to acquire a survival function (Koumenis, 2006), PRDX2
is a member of the peroxiredoxin family of antioxidant enzymes
(PRDX 1–6), which perform important functions in the mainte-
nance of the intracellular redox homeostasis (Shen et al., 2012).
Peroxiredoxins have been linked with regulation of proliferation,
differentiation, and cellular apoptosis (Park et al., 2006). Peroxire-
doxin 2 has been attributed to have both proliferative and antiap-
optotic functions, inducing carcinogenic changes (Noh et al., 2001).
A mechanism of protecting cancer cells from oxidative stress
and mediating resistance to therapy has been reported upon alter-
ations in PRDX2 expression. PRDX2 in glioma cells was decreased
by RNA silencing and increased hyperoxidation, suggesting a more
oxidizing redox environment, but apparently not altering levels of
other antioxidant enzymes, like catalase superoxide dismutase,
among others (Smith-Pearson et al., 2008). In addition, PRDX2 pro-
tein was shown to be up-regulated in radiation-resistant breast
cancer cells compared with radiation-sensitive breast cancer cells
and plays an important protective role from oxidative radical dam-
age (Wang et al., 2005). Another recent study compared the protein
expression of radiation-resistant lines of Hep-2 (RR-Hep-2) to
parental Hep-2 cells, where RR-Hep-2 acquired a more resistant
proﬁle and anti-apoptotic phenotypes than the parental line (Kim
et al., 2010). Protein levels for PRDX2 were up-regulated in the
RR-Hep-2 cells, known to play a protection function against radia-
tion induced oxidative stress (Kim et al., 2010). Stresing et al.
(2012) have related that overexpression of PRDX2 in lung meta-
static cells effectively removes the intracellular Reactive Oxygen
Species (ROS), suggesting that this condition is favorable in the
lung microenvironment to metastatic cell colonization. Most
importantly, lung cells silenced for PRDX2 were signiﬁcantly more
sensitive to oxidative stress than the parental cells. High PRDX2
expression has also been associated with renal tumors and tumors
with fewer metastases (Soini et al., 2006).
It is known that is important for developing an efﬁcacious ther-
apy to monitor the ROS in cancer cells, since most of the chemo-
therapy substances induce ROS generation with the propose to
eliminate cancer cells by apoptosis through common molecular
pathways (Maiti, 2012). But prolonged treatment with combined
drugs may also bring deleterious consequences, like reduction in
ROS level, generating resistant cells with lower ROS content than
drug sensitive cancer cells (Maiti, 2012).
Sonveaux et al. (2008) proposed a ‘‘metabolic symbiosis’’ be-
tween regions of hypoxic and aerobic cancer cells in tumors, which
contain well-oxygenated (aerobic) and poorly oxygenated (hyp-
oxic) regions. The glucose is converted to lactate in human cancer
cells when cultured under hypoxic conditions, while well-oxygen-
ated cancer cells take up lactate via monocarboxylate transporter 1
(MCT1) and use it for oxidative phosphorylation by an oxygen-
dependent expression of lactate dehydrogenase (LDHB) (Semenza,
2008). LDH has a central function in cellular metabolism, showing
a tetrameric spatial conformation composed of 2 subunits (LDHA
and LDHB). Depending upon the LDH isoform and the concentra-
tion of pyruvate and lactate, the enzyme can interconvert these
two compounds. LDHB is a key enzyme that converts lactate to
pyruvate and its expression was signiﬁcantly increased in primary
melanomas compared with nevi (Ho et al., 2012). LDH is also ex-
pressed in breast tumors (Hussien and Brooks, 2011) and gastric
tumors (Liu et al., 2009).
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studies using transfected maxillary sinus squamous cell carcinoma
and generated signiﬁcant reduced in cell proliferation upon
down-regulation of LDHB (Kinoshita et al., 2012). These results
are in accordance to the down-regulation expression of LDHB ob-
served in this study. Cytotoxic activity of red propolis in the IC50
cell samples presented reduced expression for LDHB, suggesting
an inhibition on cell proliferation activity or a proapoptotic envi-
ronment. Apparently, overexpression of both isoforms A and B sug-
gests that pyruvate metabolism has been deviated from the
tricarboxylic acid cycle to lactic acid (Liu et al., 2009). The produc-
tion of aerobic lactate where the ﬁnal step is executed by lactate
dehydrogenase is one of the characteristic phenotypes in invasive
tumor development, thus suppression of LDHB expression plays
important role in tumor invasiveness (Kim et al., 2011).
From the cytoskeleton compartment and organization, we have
identiﬁed a class II intermediate ﬁlament protein vimentin (VIM),
which was down-regulation in the red propolis treated group.
Although vimentin is normally expressed in stromal cells, regula-
tion of its expression levels have been recently associated to many
epithelial transformed tumor cells. VIM is frequently overexpressed
in tumors undergoing epithelial tomesenchymal transition (EMT), a
condition correlatedwith invasiveness and poor prognosis (Bozzuto
et al., 2010). EMT is an important procedure necessary during
embryonic development, also associated to an invasive cancer phe-
notype (Gavert and Ben-Ze’ev, 2008), characterized by a modiﬁca-
tion in the morphology with loss of polarity and contacts between
cells by the epithelial cells with increased vimentin expression
and concomitant decrease of E-cadherin (Chen et al., 2010).
Vimentin expression in epithelial tumors is considered a marker
of de-differentiation and aggressiveness, which has been recently
indicated as a novel therapeutic target (Lahat et al., 2010) and a
promising serological marker in detecting metastatic potential in
human hepatocellular carcinoma cells (Pan et al., 2012). The
down-regulation of vimentin seems to be correlated with inhibi-
tion of tumor cell proliferation and invasion (Nodale et al., 2012).
Corroborating with our results, VIM was down-regulated in Hep-
2 cells under vorinostat and/or geﬁtinib treatment (Bianchi et al.,
2011), in the erlotinib-sensitive head and neck cancer cells
(Haddad et al., 2009) and in chemotherapy resistance breast cancer
tissues (Hodgkinson et al., 2012).
Also as part of a group of the cytoskeleton compartment, the
microﬁlament-associated tubulin alpha-1A chain (TUBA1A) is a
major constituent of microtubules, also down-regulated in this
study. Cytoskeletal proteins play an important role in a series of
cell functions like as mitotic progression, proper positioning of
the nucleus, cell motility, actin ﬁlament growth, mitochondrial
tubulation, among others. In the structure of the cytoskeletal
microtubules are the a and b-tubulins (Sahab et al., 2012). Identi-
ﬁcation of differential modiﬁcations in tubulin is especially impor-
tant in the research area of cancer therapeutics. These proteins are
very signiﬁcant in cell division, which make them interesting tar-
gets for anticancer drug development (Kavallaris, 2010). Drugs
elaborated with natural products that target the tubulin and the
microtubule system, also known as anti-mitotics, are considered
a crucial component in combination chemotherapy for the treat-
ment of many cancers (Kavallaris, 2010).
The two up-regulated proteins identiﬁed in this study were
from the non-cytotoxic (6 lg/mL) red propolis treated group. One
of the proteins is a constituent of ribosome, the 60S acidic ribo-
somal protein P0 (RPLP0), the other protein identiﬁed is related
to the DNA-repair machinery, the UV excision repair protein
RAD23 homolog B isoforms 1 (RAD23B).
RAD23B is involved in nucleotide excision repair (NER) in hu-
mans by acting as a component of the XPC complex and a sensor
to bind at the sites of DNA damage (Janicijevic et al., 2003;Sugasawa et al., 2009). The XPC complex recognizes a wide spec-
trum of damaged DNA characterized by distortions of the DNA he-
lix (Sugasawa et al., 2009). Together with other recognition factors
like XPA and RPA, RAD23B is part of the pre-incision (or initial rec-
ognition) process of DNA repair and preferentially binds to plati-
num based chemotherapeutic agents, like cisplatin and UV-
damaged double-stranded DNA (Neher et al., 2010). A recent mod-
el in which XPC–RAD23B is the actual damage sensor has been pro-
posed, since after recognition RAD23B displays the XPC damage-
binding sites by decoupling it, permitting XPC (without RAD23B)
to stably bind the DNA damage (Bergink et al., 2012).
DNA repair mechanisms are important for maintaining DNA
integrity and preventing carcinogenesis. The presence of RAD23B
protein was observed in damage recognition and DNA repair of
smoking and alcohol induced DNA bulky adducts in laryngeal can-
cer risk (Abbasi et al., 2009). RAD23B was identiﬁed among a group
of up-regulated proteins that were differentially expressed as a
result of transformation following deletion of the p53 gene in lym-
phomas (Honore et al., 2008). We have identiﬁed up-regulation of
RAD23B in cells treated with low concentrations of red propolis
(6 lg/mL), where no cytotoxic activity was presented. However,
as cytotoxic activity started and presumably an apoptotic environ-
ment established, RAD23B expression in cells treated with higher
concentrations of red propolis (120 lg/mL) was altered. Upon high-
er concentrations of propolis, cells were signaled to a proapoptotic
proﬁle and RAD23 dependent DNA-repair was no more requested.
Brockstedt et al. (1998) investigated human apoptosis-associ-
ated proteins to lymphoma cell line and found up-regulation of
UV excision repair protein RAD23B and 60S acidic ribosomal pro-
tein P0 (RPLP0) on the 2-DE pattern of non-apoptotic cell group.
The apoptosis pathways are activated when other cellular response
pathways will not be efﬁcient enough (Friedberg, 2001).
RPLP0 is a protein component of the 60S subunit of the ribo-
some, localized in both cytoplasm and nucleus, which is involved
in mRNA translation. Recent reports pointed to an up-regulation
of RPLP0 under stress conditions induced by the pro-apoptotic
agent tumor necrosis factor related-apoptosis-inducing-ligand
(TRAIL) in breast cancer cells (Wilmet et al., 2011) and in plati-
num-based chemotherapy for cisplatin-resistant lung cancer line
(Kageyama et al., 2011). Alternative regulation for RPLP0 was re-
ported in proteomic approach to study global changes in protein
expression in Ras-transformed NIH3T3 mouse ﬁbroblast cell lines
(presenting overexpression of Ras), showing down-regulation of
RPLP0 in Ras transformed cells. Ras oncoproteins play important
role in the malignancy through apoptosis, invasion and deregula-
tion of cellular growth of tumors (Ji et al., 2007). Phosphor 60S
acidic ribosomal protein P0 was reduced by the action of oxythi-
amine (OT) into pancreatic cells, OT has been demonstrated in
many studies to reduce cancer cell proliferation through inhibition
of the cell cycle (Zhang et al., 2010). A recent proteomic report using
yeast cells model showed that grapefruit seed extract induced
apoptosis by down-regulation of the mitochondrial 60S ribosomal
compartment (L-14A) and up-regulation of RPLP0 (Cao et al., 2012).
Traditional anticancer treatments, such as chemotherapy and
radiotherapy, destroy tumor cells primarily by the induction of
apoptosis (Vangestel et al., 2009). The great number of publica-
tions on the antitumor action of propolis and its compounds re-
veals their potential in the development of new anticancer
agents (Sforcin and Bankova, 2011) since that propolis and its
compounds have inﬂuence in the apoptotic process on cancer cells
(Sawicka et al., 2012). Several in vitro studies have shown a proa-
poptotic effect of propolis in different types of cancer cell lines
such as MCF-7 (Seda Vatansever et al., 2010), HeLa (Orsolic and
Basic, 2003) and HL-60 (Eom et al., 2010). The apoptosis mecha-
nism induced by propolis seems to be through activating
caspase-dependent pathway (Aso et al., 2004), however it can
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the propolis extract (Sawicka et al., 2012; Watanabe et al., 2011).
Our TUNEL and Annexin-V data showed that red propolis treat-
ment markedly increased the mid- to late-apoptotic levels of
Hep-2 cells after treatment, which are in agreement with protein
proﬁles from cells treated with red propolis, demonstrated by al-
tered morphology and thus potentially may be an effective anti-
cancer agent for this kind of cancer cells.
In summary, we were able to identify candidate proteins that
participate of the regulatory metabolism of Hep-2 cells upon red
propolis treatment. Among all proteins identiﬁed with different
expression, most were down-regulated in the propolis treated
cells. Hep-2 cells treated with red propolis revealed differentially
expressed proteins related to energy production and conversion,
carbohydrate transport and metabolism, post-translational modiﬁ-
cation, protein turnover and chaperons, cytoskeleton, ribosomal
structure and repair pathway. These differences in tumor cell pro-
tein proﬁles warrant further investigations focusing on protein val-
idation trough in situ studies and protein identiﬁcation of other
tumor lines treated with red propolis extracts.
5. Conclusions
Our group has previously reported that red propolis from Brazil
is composed of complex molecules and exhibits important biolog-
ical properties with capacity to scavenge free radicals and to inhi-
bit tumor cell growth in a selective manner. Our results show that
red propolis interacts with a whole set of intracellular events and
turns to be a promising candidate to inhibit cell growth and con-
tribute to different steps related to the carcinogenesis process. Ef-
fects of some of the proteins here and elsewhere identiﬁed that
contribute to regulate the metabolism may provide further appli-
cations as molecular targets of therapeutic intervention for several
cancer types, including the ones found for Hep-2. Cell-based pro-
teomic assays are particularly valuable when searching for thera-
peutic agents once they can reveal activity against a particular
molecular target and present desirable properties such as the pro-
tein–protein interactions to permeate cells and to retain biological
activity. Although the molecular mechanisms by which red propo-
lis interacts with cell metabolism remains still unclear, further
studies including isolation of major bioactive compounds of red
propolis in different tumor and non-tumor cell lines using proteo-
mics and molecular tests to validate the differential protein
expression here observed will contribute to elucidate the antioxi-
dant and anticancer activities reported.
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